High-dose cytosine arabinoside in the treatment of resistant acute leukemia. 1985

F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
February 1987, Presse medicale (Paris, France : 1983),
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
June 1985, Seminars in oncology,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
June 1987, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
January 1984, American journal of hematology,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
October 1979, Cancer,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
December 1984, [Rinsho ketsueki] The Japanese journal of clinical hematology,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
August 1984, Ugeskrift for laeger,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
June 1985, Presse medicale (Paris, France : 1983),
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
December 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F Takaku, and A Urabe, and H Mizoguchi, and O Yamada, and Y Wakabayashi, and Y Miura, and S Sakamoto, and M Yoshida, and S Miwa, and S Asano
January 1985, Neoplasma,
Copied contents to your clipboard!